Redeye comments on Fluoguide’s Q1 2026 report. The quarter was marked by two consecutive FDA decisio...
InvesteraMera lämnar en kort kommentar på de övergripande data som presenterades från den europeiska...
Redeye comments on the recent press releases from Enviro, which highlight operational progress, secu...
Redeye comments on SynAct Pharma's Q1 report. The main event since our Q4 update was the directed sh...
Cereno Scientific has announced that its third asset, CS585 (a potent and selective agonist of the p...
Yesterday, learnd SE published a Q1 trading update for its equity stake (49.
Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for ...
We found the CMD informative of BONESUPPORT’s ongoing clinical study pipeline, spinal fusion indicat...
At 3GPP RAN4#119 in Dalian in May 2026, the working group agreed to study digital beamforming for 6G...
Under kvartalet fortsatte QBIM utvecklingen av Q-Sales och genomförde omfattande produktinvesteringa...
Redeye provides its comprehensive Q1 2026 update for the Swedish listed investment company universe,...
Biovica announced this morning an expanded work order within its Pharma Services division from a cli...
Redeye updates on Better Collective after Q1-results which were close to our expectations while the ...
* Prioritising profitability, targeting 12% EBITA margin * Building on the 15+ years of defence expe...
* aXivite drev intäkterna under Q1 * aXiphen godkänt för idisslare i Brasilien * Vårt motiverade vä...
Redeye gives an initial comment on Eisai’s FY2028 Leqembi simulation.
* Adj. EBITA -3%/-2%/+1% in '26e/'27e/'28e; North America delivers * We estimate positive EBITA grow...
* The chemical company project seemingly back on track * The Chematur MoU converted into an agreemen...
Redeye leaves a comment following today’s announcement of the final subscription terms for Alzinova’...
Botnia Gold levererade ett starkt första kvartal trots en ovanligt kall vinter med produktionsstörni...
